New Zealand markets closed

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4112-0.0366 (-8.17%)
As of 12:12PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.4478
Open0.4362
Bid0.4151 x 900
Ask0.4198 x 1000
Day's range0.4050 - 0.4599
52-week range0.3100 - 1.4800
Volume281,169
Avg. volume830,522
Market cap61.57M
Beta (5Y monthly)1.29
PE ratio (TTM)N/A
EPS (TTM)-0.2730
Earnings date15 Aug 2022 - 19 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

    David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value

  • GlobeNewswire

    Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ETSAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the quarter ending March 31, 2022. Product and Pipeline Updates and Other Corporate Developments ZIMHI According to the Centers for Disease Control

  • GlobeNewswire

    Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

    SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 16, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2022 as well as provide a business update. The company’s press release concerning